• Disease
  • Recurrent
  • Recurrent Glioblastoma
  • Mark R Gilbert

    Prominent publications by Mark R Gilbert

    KOL Index score: 10358

    PURPOSE: NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802.

    METHODS: IDH1/2 mutations were ...

    Also Ranks for: Phase Iii |  grade glioma |  risk low |  nrg oncology rtog |  idh mutant
    KOL Index score: 8914

    PURPOSE: Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and EPN_PFB that have a distinct biology and natural history. The therapeutic value of cytoreductive surgery and radiation therapy for posterior fossa ependymoma after accounting for molecular subgroup is not known.

    METHODS: Four independent nonoverlapping retrospective cohorts of posterior fossa ependymomas (n = 820) were profiled using genome-wide methylation arrays. Risk stratification models ...

    Also Ranks for: Posterior Fossa |  cytoreductive surgery |  epnpfa epnpfb |  therapeutic impact |  radiation therapy
    KOL Index score: 3132

    Background: Medulloblastoma (MB) is a rare brain tumor occurring more frequently in children in whom research has been primarily focused. Treatment recommendations in adults are mainly based on retrospective data and pediatric experience; however, molecular features and treatment tolerance differ between the 2 age groups. In adults, prognostic tools are suboptimal, late recurrences are typical, and long-term sequelae remain understudied. Treatment has not adapted to molecular ...

    Also Ranks for: Adult Mb |  pediatric experience |  molecular features |  retrospective data |  nci connect
    KOL Index score: 2686

    The NCCN Guidelines for Central Nervous System Cancers provide multidisciplinary recommendations for the clinical management of patients with cancers of the central nervous system. These NCCN Guidelines Insights highlight recent updates regarding the management of metastatic brain tumors using radiation therapy. Use of stereotactic radiosurgery (SRS) is no longer limited to patients with 3 or fewer lesions, because data suggest that total disease burden, rather than number of lesions, is ...

    Also Ranks for: Central Nervous |  srs patients |  stereotactic radiosurgery |  radiation therapy |  neoplasms humans
    KOL Index score: 2365

    Primary and metastatic tumors of the central nervous system are a heterogeneous group of neoplasms with varied outcomes and management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemotherapy and radiation as the new standard for treating patients with pure or mixed anaplastic oligodendroglioma harboring the 1p/19q codeletion. For metastatic disease, increasing evidence supports the efficacy of stereotactic radiosurgery in ...

    Also Ranks for: Central Nervous |  brain metastases |  stereotactic radiosurgery |  neoplasms humans |  1p 19q codeletion
    KOL Index score: 1130

    PURPOSE OF REVIEW: Astrocytomas are the most common primary brain tumors. We will review recent developments in the understanding of the biology of these neoplasms and recent trials demonstrating promising improvements in the survival of patients with malignant gliomas.

    RECENT FINDINGS: Temozolomide along with radiation has become the standard of care for patients with newly diagnosed glioblastoma. Nonetheless, despite this advance in treatment, these tumors remain incurable. Biological ...

    Also Ranks for: Malignant Gliomas |  brain neoplasms |  tumors review |  agents alkylating |  alternative treatment
    KOL Index score: 488

    PURPOSE: To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade astrocytoma.

    PATIENTS AND METHODS: This two-stage phase I trial determined the MTD of zotiraciclib combined with either dose-dense (Arm1) or metronomic (Arm2) temozolomide using a Bayesian Optimal Interval design; then a randomized cohort expansion compared the progression-free survival rate at 4 months (PFS4) of the two arms for an ...

    Also Ranks for: Bayesian Optimal


    Mark R Gilbert: Influence Statistics

    Sample of concepts for which Mark R Gilbert is among the top experts in the world.
    Concept World rank
    anaplastic oligoastrocytoma aoa #2
    background ependymomas #15
    recurrent highgrade astrocytoma #21
    ependymoma trial #25
    surgery tmz #26
    patients recurrent ependymoma #29
    pcv radiotherapy #29
    ependymoma background #35
    patients rela #38
    treatment ependymomas #40
    ependymoma chemotherapy #44
    glioblastoma standard #48
    ependymoma antineoplastic #65
    ependymomas rare #66
    rtog 9802 #76
    eortc 26951 #79
    nciconnect #82
    oligoastrocytoma aoa #85
    patients epnpfb #87
    rtog 9402 #90
    1p 19q codeleted #92
    tumors nci #94
    nci connect #95
    recurrent ependymomas #95

    Key People For Recurrent Glioblastoma

    Top KOLs in the world
    Roger Stupp
    newly diagnosed glioblastoma radiation therapy adjuvant temozolomide
    Martin J van den Bent
    recurrent glioblastoma response assessment brain metastases
    Michael Weller
    glioma cells newly diagnosed glioblastoma multiple sclerosis
    Alba Ariela Brandes
    recurrent glioblastoma elderly patients breast cancer
    Patrick Yung Chih Wen
    recurrent glioblastoma brain metastases response assessment
    Warren P Mason
    newly diagnosed glioblastoma adjuvant temozolomide phase iii

    Mark R Gilbert:Expert Impact

    Concepts for whichMark R Gilberthas direct influence:Recurrent glioblastoma,  Newly diagnosed glioblastoma,  Bevacizumab patients,  Radiation therapy,  Recurrent ependymoma,  Diagnosed glioblastoma,  Adjuvant treatment,  Patients glioblastoma.

    Mark R Gilbert:KOL impact

    Concepts related to the work of other authors for whichfor which Mark R Gilbert has influence:Brain metastases,  Stereotactic radiosurgery,  Intracranial ependymoma,  Leptomeningeal metastasis,  Radiation therapy,  Gbm patients,  Ependymal tumors.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA | Center for Cancer Research and Neuro-Oncology Branch (MRG, TSA), National Cancer Institute, Bethesda, MD, USA. | Department of Otolaryngology-Head